We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.72 | 0.95% | 76.20 | 76.17 | 76.27 | 29,486 | 13:27:32 |
From Apr 2021 to Apr 2024
By Sabela Ojea
AstraZeneca PLC said Monday that its Forxiga drug has been approved in the European Union for the treatment of chronic kidney disease in adults with or without type 2 diabates.
The British-Swedish drugmaker said the approval is based on positive results from the DAPA-CKD phase three trial.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
August 09, 2021 02:53 ET (06:53 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
